IL17A and psoriatic arthritis: Likewise, IL-31 has been correlated with TH17 cytokines in psoriatic arthritis,27,28 and nemolizumab has been shown to effectively decrease TH17 and IL-17 responses.24 Downregulation in acute phase response signaling, myeloid cell movement, leukocyte migration, and the proinflammatory cytokine, interferon γ, further support a decrease in systemic inflammation.29,30 Altogether, these results show plasma biomarkers of inflammation were downregulated in the nemolizumab group compared with the placebo group.